Mrs Sonia Fox BSc

Mrs Sonia Fox

Institute of Cancer and Genomic Sciences
Deputy Director of Operations

Contact details

Cancer Research UK Clinical Trials Unit
Institute of Cancer and Genomic Sciences
College of Medical and Dental Sciences
University of Birmingham
B15 2TT

Sonia Fox is the Deputy Director of Operations at the Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham.


BSc Biological Sciences, Honours in Pharmacology with Industrial Experience


Sonia Fox is the Deputy Director of Operations at the Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham.

She graduated with a Biological Sciences, Honours in Pharmacology with Industrial Experience Degree in 2007.

She joined the Birmingham Clinical Trials Unit (BCTU) at the University of Birmingham as a Trial Administrator in 2007. She was promoted to Trial Coordinator at the CRCTU in 2009, Senior Trial Coordinator in 2011 and Trial Management Team Leader for Haematology in 2017. Her experience has been predominately in early phase trials of haematological malignancies, with a particular interest in myeloid studies and novel agents.

She was appointed as Deputy Director of Operations of CRCTU in 2024.



Current projects

Sonia Fox has contributed to the design, set-up and/or management of the following trials:

  • REFRACT (follicular lymphoma)
  • PACE (Acute Myeloid Leukaemia)
  • FEDORA (myelofibrosis)
  • AMMO (Myelodysplastic syndrome/ Myeloproliferative Neoplasm overlap)
  • PRIZM+ (CNS Lymphoma)
  • VICTOR (Acute Myeloid Leukaemia)
  • PROMISE (myelofibrosis)
  • STELLAR (Richter’s Syndrome)
  • TAMARIN (Myeloproliferative Neoplasms)
  • AZTEC (Graft versus Host Disease)
  • PHAZAR (Accelerated phase Myeloproliferative Neoplasms)
  • TIER (CNS Lymphoma)
  • RomiCar (T-cell lymphoma)
  • ELASTIC (Myelodysplastic syndrome)
  • CyCLLe (CLL)
  • MAJIC (Myeloproliferative Neoplasms)
  • RAvVA (Acute Myeloid Leukaemia/ Myelodysplastic syndrome)
  • ROMAZA (Acute Myeloid Leukaemia)
  • De-Iron (Myelodysplastic syndrome)
  • TACE-2 (Hepatocellular carcinoma)


Zijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, Rebecca H Boucher, Aimee Jackson, Rachel S Fletcher, Dorian Forte, Jose-Ezequiel Martin, Sonia Fox, James Roberts, Rachel Glover, Erica Harris, Hanna Bridges, Luigi Grassi, Alba Rodriguez-Meira, Adam J Mead, Steven Knapper, Joanne Ewing, Nauman M Butt, Manish Jain, Sebastian Francis, Fiona J Clark, Jason Coppell, Mary F McMullin, Frances Wadelin, Srinivasan Narayanan, Dragana Milojkovic, Mark W Drummond, Mallika Sekhar, Hesham El Daly, Judy Hirst, Maike Paramor, E Joanna Baxter, Anna L Godfrey, Claire N Harrison, Simón Méndez-Ferrer. “Tamoxifen reduces 1 mitochondrial respiration, oncogenic JAK-STAT signaling and mutant allele burden in a subset of myeloproliferative neoplasms -TAMARIN Phase II study” Nature Communications (2023)14:7725.

Loke J, Upasani V, Gaskell C, Fox S, Fletcher R, Thomas C, Hopkins L, Kumari A, Tang T, Yafai E, Boucher R, Homer V, Toth A, Chan YLT, Randall K, Rider T, O'Nions J, Drew V, Pillai A, Dungarwalla M, Murray D, Khan A, Wandroo F, Moore S, Krishnamurthy P, Huang YJ, Knapper S, Byrne J, Zhao R, Craddock C, Parry H, Moss P, Stanworth SJ, Lowe DM. Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes. Br J Haematol. 2023 Aug;202(3):498-503. doi: 10.1111/bjh.18894. Epub 2023 Jun 12. PMID: 37303189.

Claire N. Harrison, Jyoti Nangalia, Rebecca Boucher, Aimee Jackson, Christina Yap,Jennifer O’Sullivan, Sonia Fox, Isaak Ailts, Amylou C. Dueck, Holly L. Geyer, Ruben A. Mesa, William G. Dunn, Eugene Nadezhdin, Natalia Curto-Garcia, Anna Green, Bridget Wilkins, Jason Coppell, John Laurie, Mamta Garg,  Joanne Ewing, Steven Knapper, Josephine Crowe, Ioannis Koutsavlis, Anna Godfrey, Siamak Arami, Mark Drummond, Jennifer Byrne, Fiona Clark, Carolyn Mead-Harvey, ElizabethJoanna Baxter, Mary Frances McMullin, Adam Mead. “Ruxolitinib versus Best Available Therapy for PV intolerant or resistant to Hydroxycarbamide in a Randomized trial”. Journal of Clinical Oncology 41 (19). 01 May 2023.

Dillon R, Maycock S, Jackson A, Fox S, Freeman S, Craddock C, Thomas C, Homer E, Leahy J, Mamwell A, Potter N, Russell N, Wei A, Ommen HB, Hemmaway C, Knapper S, Billingham L. Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial. BMC Cancer. 2022 Nov 14;22(1):1174. doi: 10.1186/s12885-022-10221-2. 

Vasiliki Symeonidou, Marlen Metzner, Batchimeg Usukhbayar, Aimee E. Jackson, Sonia Fox, Charles F. Craddock, Paresh Vyas. “Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapy.” eJHaem. 08 July 2022.

Justin Loke, Marlen Metzner, Rebecca Boucher, Aimee Jackson, Louise Hopkins, Jiri Pavlu, Eleni Tholouli, Mark Drummond, Andy Peniket, Rebecca Bishop, Sonia Fox, Paresh Vyas, Charles Craddock. (2021) “Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy”. British Journal of Haematology, 2021 September 06. Short report

O’Sullivan, J; Hamblin, A; Yap, C; Fox, S; Boucher, R; Panchal, A; Aliman, S; Dreau, H; Howard, K; Ware, P; Cross, N; McMullin, M; Harrison, C; Mead, A; (2019) “The poor outcome in high molecular risk, hydroxycarbamide resistant/intolerant ET is not ameliorated by ruxolitinib”; Blood. 2019 Dec 5;134(23):2107-2111.

Thomas A Fox, Gillian A Horne, Charles Craddock, Gordon Cook, Stephen O’Brien, Sonia Fox, Anna Hockaday, Graham Silk, and Peter Hillmen (2019) “Trial re-investment to build better research for better impact”,The Lancet (correspondence). Vol 394 August 24, 2019,  p635.

Appleby, N; Eyre .A, T; Cabes, M; Jackson, A; Boucher, R; Yates, F; Fox, S; Rawston, A; Hillmen, P; Schuh, A: “The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease” BMC Cancer 19, 471 (2019)

Harrison, CN; Mead, AJ; Panchal, A; Fox, S; Yap, C; Gbandi, E; Houlton, A; Aliman, S; Ewing, J; Wood, M; Chen, F; Coppell, J; Panoskaltsis, N; Knapper, S; Ali, S; Hamblin, A; Scherber, R; Dueck, AC; Cross, NCP; Mesa R; McMullin, MF. (2017). “Ruxolitinib versus Best Available Therapy for ET intolerant or resistant to Hydroxycarbamide in a Randomized trial”. Blood, 130:1889-1897